| Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial P Caraceni, O Riggio, P Angeli, C Alessandria, S Neri, FG Foschi, ... The Lancet 391 (10138), 2417-2429, 2018 | 451 | 2018 |
| Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial A Mangia, N Minerva, D Bacca, R Cozzolongo, GL Ricci, V Carretta, ... Hepatology 47 (1), 43-50, 2008 | 340 | 2008 |
| Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B P Lampertico, M Viganò, GG Di Costanzo, E Sagnelli, M Fasano, ... Gut 62 (2), 290-298, 2013 | 154 | 2013 |
| Changing pattern of chronic hepatitis D in Southern Europe F Rosina, P Conoscitore, R Cuppone, G Rocca, A Giuliani, R Cozzolongo, ... Gastroenterology 117 (1), 161-166, 1999 | 146 | 1999 |
| Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection L Caradonna, ML Mastronardi, T Magrone, R Cozzolongo, R Cuppone, ... Current pharmaceutical design 8 (11), 995-1005, 2002 | 111 | 2002 |
| Epidemiology of HCV infection in the general population: a survey in a southern Italian town R Cozzolongo, AR Osella, S Elba, J Petruzzi, G Buongiorno, V Giannuzzi, ... Official journal of the American College of Gastroenterology| ACG 104 (11 …, 2009 | 102 | 2009 |
| Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies VC Di Maio, V Cento, I Lenci, M Aragri, P Rossi, S Barbaliscia, M Melis, ... Liver international 37 (4), 514-528, 2017 | 99 | 2017 |
| Ribavirin treatment for chronic hepatitis D: a pilot study A Garripoli, V Di Marco, R Cozzolongo, C Costa, A Smedile, A Fabiano, ... Liver 14 (3), 154-157, 1994 | 96 | 1994 |
| Determinants of relapse after a short (12 weeks) course of antiviral therapy and re‐treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype … A Mangia, N Minerva, D Bacca, R Cozzolongo, E Agostinacchio, F Sogari, ... Hepatology 49 (2), 358-363, 2009 | 78 | 2009 |
| Real-world experience with obeticholic acid in patients with primary biliary cholangitis D D’Amato, A De Vincentis, F Malinverno, M Viganò, D Alvaro, M Pompili, ... JHEP Reports 3 (2), 100248, 2021 | 53 | 2021 |
| Artificial neural networks for the prediction of response to interferon plus ribavirin treatment in patients with chronic hepatitis C PA Maiellaro, R Cozzolongo, P Marino Current pharmaceutical design 10 (17), 2101-2109, 2004 | 52 | 2004 |
| On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites P Caraceni, M Tufoni, G Zaccherini, O Riggio, P Angeli, C Alessandria, ... Journal of Hepatology 74 (2), 340-349, 2021 | 50 | 2021 |
| Physical activity and low glycemic index Mediterranean diet: main and modification effects on NAFLD score. Results from a randomized clinical trial I Franco, A Bianco, A Mirizzi, A Campanella, C Bonfiglio, P Sorino, ... Nutrients 13 (1), 66, 2021 | 44 | 2021 |
| Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-α/Ribavirin L Amati, L Caradonna, T Magrone, ML Mastronardi, R Cuppone, ... Current pharmaceutical design 8 (11), 981-993, 2002 | 44 | 2002 |
| Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin A Andriulli, V Di Marco, M Margaglione, AM Ippolito, G Fattovich, ... Journal of Hepatology 60 (1), 16-21, 2014 | 41 | 2014 |
| Real‐life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study M Persico, A Aglitti, M Milella, C Coppola, V Messina, E Claar, I Gentile, ... Liver International 39 (10), 1852-1859, 2019 | 39 | 2019 |
| Aerobic physical activity and a low glycemic diet reduce the AA/EPA ratio in red blood cell membranes of patients with NAFLD V Tutino, V De Nunzio, MG Caruso, C Bonfiglio, I Franco, A Mirizzi, ... Nutrients 10 (9), 1299, 2018 | 39 | 2018 |
| Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? VC Di Maio, V Cento, M Aragri, S Paolucci, T Pollicino, N Coppola, ... Journal of hepatology 68 (3), 597-600, 2018 | 39 | 2018 |
| Onset of type 1 diabetes mellitus during peginterferon α-2b plus ribavirin treatment for chronic hepatitis C R Cozzolongo, C Betterle, P Fabris, MP Albergoni, E Lanzilotta, ... European journal of gastroenterology & hepatology 18 (6), 689-692, 2006 | 38 | 2006 |
| Evaluation of cellular immune responses and soluble mediators in patients with chronic hepatitis C virus (cHCV) infection E Jirillo, B Greco, L Caradonna, R Satalino, V Pugliese, R Cozzolongo, ... Immunopharmacology and immunotoxicology 17 (2), 347-364, 1995 | 38 | 1995 |
Angelo AndriulliCasa Sollievo SofferenzaVerified email at operapadrepio.it
